Update on the prevalence and spread of macrolide- and lincosamide-resistant staphylococcal and streptococcal species

Reviews and Research in Medical Microbiology

Volumn 16, Issue 3, 2005, Pages 117-123

  DiPersio, Joseph R ^a   DiPersio, Linda P ^a  

^a SUMMA HEALTH SYSTEM   (United States)

Author keywords

Macrolide resistant Staphylococcus; Macrolide resistant Streptococcus; MLSB resistance; MLSB resistance in gram positive cocci; MLSB resistant Staphylococcus; MLSB resistant Streptococcus

Indexed keywords

CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; KETOLIDE; LINCOSAMIDE; MACROLIDE; MESSENGER RNA; MIKAMYCIN B; RIBOSOME PROTEIN; TELITHROMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG BINDING; DRUG MECHANISM; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GRAM POSITIVE COCCI; MEF GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MSR GENE; NONHUMAN; PENICILLIN RESISTANCE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME; VGA GENE;

EID: 23044435723     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.revmedmi.0000174306.26027.e3     Document Type: Review

References (59)

1. Lai CJ, Weisblum B. Altered methylation of ribosomal RNA in an erythromycin-resistant strain of Staphylococcus aureus. Proc Natl Acad Sci USA 1971; 68:856-860.
2. McGuire JM, Bunch RL, Anderson RC, Boaz HE, Flynn EH, Powell HM, et al. 'Ilotycin', a new antibiotic. Antibiotic Chemother 1952; 2:281-283.
3. Fluit ADC, Visser MR, Schmitz FJ. Molecular detection of antimicrobial resistance. Clin Microbiol Rev 2001; 14:836-871.
4. Franceschi F, Kanyo Z, Scherer EC, Sutcliffe J. Macrolide resistance from the ribosome perspective. Current Drug Targets-Infectious Disorders 2004; 4:177-191.
5. Nakajima Y. Mechanisms of bacterial resistance to macrolide antibiotics. J Infect Chemother 1999; 5:61-74.
6. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34:482-492.
7. Roberts M, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrobiol Agents Chemother 1999; 43:2823-2830.
8. Arthur M, Brisson-Noel A, Courvalin P. Origin and evolution of genes specifying resistance to macrolide, lincosamide and streptogramin antibiotics: data and hypothesis. J Antimicrob Chemother 1987; 20:783-802.
9. Weisblum B. Erythromycin resistance by ribosomal modification. Antimicrob Agents Chemother 1995; 39:577-585.
10. Tait-Kamradt A, Davies T, Appelbaum PC, Depardieu F, Courvalin P, Petitpas J, et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pnuemoniae from eastern Europe and North America. Antimicrobial Agents Chemother 2000; 44:3395-3401.
11. Allignet J, Loncle V, Solh NE. Sequence of a staphylococcal plasmid gene vga, encoding a putitive ATP-binding protein involved in resistance to virginiamycin A-like antibiotics. Gene 1992; 117:45-51.
12. Luna VA, Coates P, Eady EA, Cove JH, Nguyen TT, Roberts MC. A variety of gram-positive bacteria carry mobile mef genes. J Antimicrob Chemother 1999; 44:19-25.
13. Brisson-Noel A, Courvalin P. Nucleotide sequence of gene linA encoding resistance to lincosamides in Staphylococcus haemolyticus. Gene 1986; 43:247-253.
14. Haight TH, Finland M. Resistance of bacteria to erythromycin. Proc Soc Exp Biol Med 1952; 81:183-188.
15. Westh H, Hougaard DM, Vuust J, Rosdahl VT. Prevalence of erm gene classes in erythromycin-resistant Staphylococcus aureus strains between 1959 and 1988. Antimicrob Agents Chemother 1995; 39:369-373.
16. Nicola FC, McDougal LK, Biddle JW, Tenover FC. Characterization of erythromycin-resistant isolates of Staphylococcus aureus recovered in the United States from 1958 through 1969. Antimicrob Agents Chemother 1998; 42:3024-3027.
17. Schmitz FJ, Sadursky R, Kray A, Boos M, Geisel R, Kohrer K, et al. Prevalence of macrolide resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university hospitals. J Antimicrob Chemother 2000; 45:891-894.
18. Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrobial Agents Chemother 1999; 43:1062-1066.
19. Schmitz FJ, Petridou J, Fluit AC, Hadding U, Peters G, Eiff CvE. Distribution of macrolide-resistant genes in Staphylococcus aureus blood-culture isolates from fifteen German university hospitals. Eur J Clin Microbiol Infect Dis 2000; 19:385-387.
20. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3:171-196.
21. Song JH, Chang HH, Suh JY, Ko KS, Jung SI, Oh WS, et al. Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of resistant pathogens (ANSORP). J Antimicrob Chemother 2004; 53:457-463.
22. Bozdogan B, Bogdanovich T, Kosowska K, Jacobs MR, Appelbaum PC. Macrolide resistance in Streptococcus pneumoniae: Clonality and mechanisms of resistance in 24 countries. Curr Drug Targets Infect Disord 2004; 4:169-176.
23. Farrell DJ, Jenkins SJ. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. J Antimicrob Chemother 2004; 54:Sl, i17-i22.
24. Hoban DJ, Wierzbowski AK, Nichol K, Zhanel GG. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimicrobial Agents Chemother 2001; 45:2147-2150.
25. Farrell D, Morrissey I, Bakker S, Morris L, Buckridge S, Felmingham D. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J Clin Microbiol 2004; 42:764-768.
26. Seppala H, Skurnik M, Soini H, Roberts MC, Huovinen P. A novel erythromycin resistant methylase gene (ermTR) in Streptococcus pyogenes. Antimicrob Agents Chemother 1998; 42:257-262.
27. Trieu-Cuot P, Poyart-Salmeron C, Carlier C, Courvalin P. Nucleotide sequence of the erythromycin resistance gene of the conjugative transposon Tn1545. Nucl Acids Res 1990; 18:36-60.
28. Gay K, Stevens DS. Structure and dissemination of a chromosomal insertion element encoding macrolide efflux in Streptococcus pneumoniae. J Infect Dis 2001; 184:56-65.
29. Canu A, Malbruny B, Coquemont M, Davies TA, Appelbaum PC, Leclercq R. Diversity of ribosomal mutations confering resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46:125-131.
30. Farrell DJ, Douthwaite S, Morrissey I, Bakker S, Poehlsgaard J, Jakobsen L, et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob Agents Chemother 2003; 47:1777-1783.
31. Lowbury EJ, Hurst L. The sensitivity of staphylococci and other wound bacteria to erythromycin, oleandomycin and spiramycin. J Clin Pathol 1959; 12:163-169.
32. Billal DS, Hotomi M, Yamauchi K, Fujihara K, Tamura S, Kuki K, et al. Macrolide-resistant genes of Streptococcus pyogenes isolated from the upper respiratory tract by polymerase chain reaction. J Infect Chemother 2004; 10:115-120.
33. Inoue M, Kohno S, Kaku M, Yamaguchi K, Igari J, Yamanaka K. Protekt 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan. Intern J Infect Dis 2005; 9:27-36.
34. Katz KC, McGeer AJ, Duncan CL, Ashi-Sulaiman A, Willey BM, Sarabia A, et al. Emergence of macrolide resistance in throat culture isolates of group A streptococci in Ontario, Canada, in 2001. Antimicrob Agents Chemother 2003; 47:2370-2372.
35. Brown S, Rybak M. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. J Antimicrob Chemother 2004; 54 (Suppl. S1):i7-i15.
36. Canton R, Loza E, Morosini MI, Baquero F. Antimicrobial resistance amongst isolates of Streptococcus pneumoniae and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. J Antimicrob Chemother 2002; 50 (Suppl. S1):9-24.
37. Bozdogan B, Appelbaum PC. Macrolide resistance in streptococci and Haemophilus influenzae. Clin Lab Med 2004; 24:455-475.
38. Eickhoff TC, Klein JO, Daly AK, Ingall D, Finland M. Neonatal sepsis and other infections due to group B beta-hemolytic streptococci. N Engl J Med 1964; 271:1221-1228.
39. Murdoch DR, Relle LB. Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10 year perspective. Antimicrob Agents Chemother 2001; 45:3623-3624.
40. Lin FY, Azimi PH, Weisman LE, Philips JB, Regan J, Clark P, et al. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998. Clin Infect Dis 2000; 31:76-79.
41. Andrews JI, Diekema DJ, Hunter SK, Rhomberg PR, Pfaller MA, Jones RN, et al. Group B streptococci causing neonatal blood-stream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the western hemisphere. Am J Obstet Gynecol 2000; 183:859-862.
42. DiPersio LP, Fry KC, DiPersio JR. Activity of telithromycin against group B Streptococcus isolates exhibiting high rates of erthromycin and clindamycin resistance. 104th General Meeting of the American Society for Microbiology. Washington, DC: May 2004 [abstract A-006].
43. Diekema DJ, Andrews JI, Huynh H, Rhomberg PR, Doktor SR, Beyer J, et al. Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci. J Clin Microbiol 2003; 41:2659-2661.
44. Betriu C, Culebras E, Gomez M, Rodriguez-Avial I, Sanchez BA, Agreda MC, et al. Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae. Antimicrob Agents Chemother 2003; 47:1112-1114.
45. De Mouy D, Cavallo JD, Leclercq R, Fabre R. Antibiotic susceptibility and mechanisms of erythromycin resistance in clinical isolates of Streptococcus agalactiae: French multicenter study. Antimicrob Agents Chemother 2001; 45:2400-2402.
46. Acikgoz ZC, Almayanlar E, Gamberzade S, Gocer S. Macrolide resistance determinants of invasive and non-invasive group B streptococci in a Turkish hospital. Antimicrob Agents Chemother 2004; 48:1410-1412.
47. Hsueh PR, Teng LJ, Lee LN, Ho SW, Yang PC, Luh KT. High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan. Antimicrob Agents Chemother 2001; 45:3205-3208.
48. Perez-Trallero E, Vicente D, Montes M, Marimon JM, Pineiro L. High proportion of pharyngeal carriers of commensal streptococci resistant to erythromcin in Spanish adults. J Antimicrob Chemother 2001; 48:225-229.
49. Ioannidou S, Papaparaskevas J, Tassios PT, Foustoukou M, Legakis NJ, Vatopoulos AC. Prevalence and characterization of the mechanism of macrolide, lincosamide and streptogramin resistance in viridans group streptococci. Int J Antimicrob Agents 2003; 22:626-629.
50. Aracil B, Minambres M, Oteo J, Torres C, Gomez-Garces JL, Alos JI. High prevelance of erythromycin-resistant and clindamycin-susceptible (M-Phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria. J Antimicrob Chemother 2001; 48:592-595.
51. Gordon KA, Beach ML, Biedenbach DL, Jones RN, Rhomberg PR, Mutnick AH. Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY antimicrobial surveillance program (1997-2000). Diag Microbiol Infect Dis 2002; 43:157-162.
52. Kataja J, Huovinen P, Skurnik M, Resistance TFSG, Seppala H. Erythromycin resistance genes in group a streptococci in Finland. Antimicrob Agents Chemother 1999; 43:48-52.
53. Zolezzi PC, Laplana LM, Calvo CR, Cepero PG, Erazo MC, Gomez-Lus R. Molecular basis of resistance to macrolides and other antibiotics in commensal viridans group streptococci and Gemella spp. and transfer of resistance genes to Streptococcus pneumoniae. Antimicrob Agents Chemother 2004; 48:3462-3467.
54. Watanakunakorn C. Clindamycin therapy of Staphylococcus aureus endocarditis: clinical relapse and developement of resistance to clindamycin, lincomycin and erythromycin. Am J Med 1976; 60:419-425.
55. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257-1260.
56. Lewis JS, Jorgensen JH. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis 2005; 40:280-285.
57. NCCLS. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. vol. M100-S15. Wayne, PA: NCCLS; 2005.
58. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 2003; 41:4740-4744.
59. Hoban DJ, Zhanel GG, Karlowsky JA. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Diag Microbiol Infect Dis 1999; 35:37-44.